Jardiance (empagliflozin)approved for Wider Range of Patients with Heart Failure
11 Marzo 2022
The U.S. Food and Drug Administration approved Jardiance (empagliflozin) to reduce the risk of cardiovascular death and hospitalization for heart failure in adults. Jardiance was
